SGB-3908 not checked

Suzhou Sanegene Bio Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered”In the company’s words, NCT06501586 on ClinicalTrials.gov
Tested for
Hypertension,Essential
Main trialPhase 1
“The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects. The study will be a single ascending dose (SAD) phase.”In the company’s words, NCT06501586 on ClinicalTrials.gov

Other drugs for Hypertension,Essential

All 18 drugs for Hypertension,Essential

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 7 Apr 2025 Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SGB-3908

Following is part of Solo: you see every change to SGB-3908 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in